文献速递儿童呼吸

针对儿童哮喘药物的定制依从性激励:一项随机临床试验

Tailored Adherence Incentives for Childhood Asthma Medications: A Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2025-01-01

这项随机临床试验在高风险、以少数族裔为主的5-12岁哮喘儿童中,评估经济激励增强的移动健康干预对吸入性预防药物依从性的影响。结果显示,全额干预组在实验期依从性比主动对照组高15个百分点(95%CI 2-29),但干预停止后观察期未见持续效果。

要点

  • 全额干预(每日短信提醒+每周依从反馈+每日最高1美元经济激励)可提高实验期吸入维持药物依从性。
  • 干预停止后3个月观察期,各组依从性无差异,未见持续效果。
  • 研究纳入既往一年至少2次需全身激素哮喘发作的5-12岁儿童。

核心结论

  • 经济激励增强的移动健康干预相比主动对照组提高了吸入性预防药物依从性,但干预停止后无持续效果。

研究设计与样本

  • 随机临床试验,2019年9月至2022年6月在美国中大西洋地区大型儿科健康系统开展,纳入5-12岁、每日使用预防性吸入器且既往一年至少2次需全身激素哮喘发作的儿童。
  • 106名儿童随机,99名有至少1个月监测数据;平均(SD)年龄8.0(2.3)岁,56名男性(57%),43名女性(43%),81名(82%)为非西班牙裔黑人。
  • 干预包括1个月导入期、3个月实验期和3个月观察期,使用电子吸入器传感器监测。

主要发现

  • 实验期全额干预组吸入维持药物依从性比主动对照组高15个百分点(95%CI 2-29个百分点)。
  • 观察期各组依从性无差异证据。

关键数值与推荐

  • 全额干预:每日短信用药提醒、每周依从反馈及增益框架经济激励最高每日1美元;混合干预:每日短信提醒和每周依从反馈;主动对照:无提醒、反馈或激励。
  • 主要结局为实验期吸入维持药物依从性,次要结局为观察期依从性。

临床怎么用

  • 对高风险哮喘儿童,可考虑结合短信提醒、依从反馈和经济激励的短期干预以提高预防药物依从性。
  • 需注意干预停止后依从性可能回落,应规划长期维持策略。

局限性

  • 干预停止后无持续效果。
  • 样本量较小(99名有监测数据),可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Differential adherence to efficacious preventive medications is one potentially modifiable driver of racial disparities in childhood asthma outcomes. OBJECTIVE: To determine the effect of a financial incentive-enhanced intervention on adherence to inhaled asthma preventive medication in a high-risk, predominantly racially minoritized cohort of children with asthma. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized clinical trial conducted from September 2019 through June 2022 at a large mid-Atlantic pediatric health system in the US. Children were eligible if they were between 5 and 12 years old, prescribed a preventive inhaler for daily use, and had at least 2 asthma exacerbations requiring systemic steroids in the preceding year. Data were analyzed from December 2022 to December 2024. INTERVENTION: Inhaled medication use was monitored using electronic inhaler sensors over a 7-month period. Families who completed a 1-month run-in interval were randomized to 1 of 3 arms for a 3-month experiment interval: (1) daily text message medication reminders, weekly adherence feedback, and gain-framed, financial incentives of up to $1 per day (full intervention); (2) daily text message medication reminders and weekly adherence feedback (hybrid intervention); or (3) no reminders, feedback, or incentives (active control). Medication adherence monitoring then continued for a 3-month observation interval, where all arms reverted to active control conditions. MAIN OUTCOMES AND MEASURES: The primary outcome was adherence to inhaled maintenance medication during the experiment; secondary outcomes included adherence during the observation phase. The study was powered to detect a difference in average monthly adherence between the full intervention and active control condition. RESULTS: Of the 106 children randomized, 99 had at least 1 month of monitoring data (56 male [57%] and 43 female [43%]; mean [SD] age, 8.0 [2.3] years). Most participants (81 [82%]) identified as non-Hispanic Black and demographic and clinical characteristics were similar across study arms. During the experiment interval, participants receiving the full intervention had a 15-percentage point (95% CI, 2-29 percentage points) higher inhaled maintenance medication adherence compared with participants in the active control. There was no evidence of adherence differences in the observation interval. CONCLUSION AND RELEVANCE: While a financial incentive-enhanced mobile health intervention led to higher inhaled preventive medication adherence as compared with the active control group, there was no evidence for enduring effect after the intervention components ceased, consistent with other studies that include financial incentives to encourage behavior change. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03907410.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Kenyon CC, Quarshie WO, Xiao R, et al. Tailored Adherence Incentives for Childhood Asthma Medications: A Randomized Clinical Trial. JAMA Pediatr. 2025. PMID: 40094638. doi:10.1001/jamapediatrics.2025.0010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。